Electroacupuncture Inhibits NLRP3-Mediated Microglial Pyroptosis to Ameliorate Chronic Neuropathic Pain in Rats.

Researchers investigated how electroacupuncture (EA) helps relieve chronic nerve pain in rats with damaged nerves. Nerve pain, which affects many people after injury or disease to the nervous system, can be severe and difficult to treat. In this study, scientists created a nerve injury model in rats and then treated them with electroacupuncture at two specific points: GV20 (on the top of the head) and ST36 (on the lower leg). The treatments were given daily for two weeks. The researchers measured how the animals responded to touch and heat to assess their pain levels. They also examined spinal cord tissue to understand what was happening at the cellular level. The results showed that electroacupuncture significantly reduced pain sensitivity and decreased inflammation in the spinal cord. Specifically, EA worked by preventing a harmful inflammatory process called pyroptosis in microglial cells, which are immune cells in the nervous system. This process involves a protein complex called NLRP3 that triggers inflammation and cell death. Electroacupuncture effectively blocked this pathway, reducing the release of inflammatory chemicals like IL-1β and TNF-α. When researchers used a drug to block the same pathway, it produced similar pain relief, confirming that this mechanism is important for EA's effects. These findings suggest that electroacupuncture may be an effective treatment option for people suffering from chronic nerve pain by targeting specific inflammatory processes in the nervous system. If you're considering acupuncture for chronic pain, consult with a licensed acupuncturist who has experience treating neuropathic conditions.

This preclinical study investigated electroacupuncture's mechanisms in treating chronic neuropathic pain using a Chronic Constriction Injury (CCI) model in male Sprague-Dawley rats. EA was administered at GV20 and ST36 daily for 14 consecutive days beginning 7 days post-surgery. Results demonstrated significant improvements in mechanical withdrawal threshold (MWT) and paw withdrawal latency (PWL), indicating reduced pain hypersensitivity. Mechanistic analysis revealed EA downregulated pyroptosis-related proteins including NLRP3, N-GSDMD, Cleaved Caspase-1, IL-18, and IL-1β specifically in spinal microglial cells, not neurons or astrocytes. Pro-inflammatory cytokines IL-1β and TNF-α were significantly reduced in spinal tissue. Pharmacological validation using NLRP3 antagonist MCC950 produced comparable analgesic effects and blocked EA's anti-pyroptosis activity, confirming NLRP3 inflammasome as the primary therapeutic target. Clinical implication: EA demonstrates targeted anti-inflammatory effects through microglial NLRP3 inflammasome inhibition, supporting its application for chronic neuropathic pain management, particularly in conditions involving neuroinflammation.